C4X Discovery Release: Acquisition Of Drug-Discovery Technologies From MolPlex Ltd
Proprietary platform technology further augments C4X Discovery’s drug discovery engine
12 July, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the acquisition of a suite of advanced drug-discovery technologies from MolPlex Ltd (the “Molplex Technologies”).
The MolPlex Technologies comprise a pioneering software-based system that combines state-of-the art chemoinformatics, computational chemistry and artificial intelligence to optimize the drug development process.
Currently, C4XD has the only technology in the world (Conformetrix) that can use experimentally-determined solution-structures to design drug molecules that are optimally shaped to provide potency and selectivity. The MolPlex Technologies will complement this by enabling C4XD to not only generate the chemical starting point for such design programmes in rapid time, but to also predict whether the resulting molecules have the ‘druggable’ qualities required for human administration (e.g. absorption, solubility and metabolic stability), thereby reducing the cost, time and attrition associated with early development and increasing the likelihood of eventual clinical success.
The MolPlex Technologies were originally developed at Newcastle University and have three aspects:
• a vast in silico library of compounds that can be used for virtual screening to provide quick chemical starting points for new development programmes;
• a molecular simulations system that enables medicinal chemists to understand the interactions between drugs and their targets;
• algorithms that can predict the physiochemical properties of lead molecules (such as absorption, distribution, metabolism, excretion, cell permeability, solubility and plasma-protein binding), enabling rapid optimisation of candidates for clinical testing.
Dr Clive Dix, CEO of C4X Discovery, said: “These new technologies, which we have brought into the business on very economical terms, complement our existing platform and add to our ability to capitalise on the identification of high-value targets from our Taxonomy3® technology to generate drug candidates with greater clinical and commercial differentiation. We are rapidly building an internal pipeline of exciting therapeutic programmes and moving steadily towards realising our goal of becoming the world’s most productive drug discovery and development company.”
C4XD acquired the technologies from MolPlex Ltd, which is currently in administration, for a non-material amount.
12 July, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the acquisition of a suite of advanced drug-discovery technologies from MolPlex Ltd (the “Molplex Technologies”).
The MolPlex Technologies comprise a pioneering software-based system that combines state-of-the art chemoinformatics, computational chemistry and artificial intelligence to optimize the drug development process.
Currently, C4XD has the only technology in the world (Conformetrix) that can use experimentally-determined solution-structures to design drug molecules that are optimally shaped to provide potency and selectivity. The MolPlex Technologies will complement this by enabling C4XD to not only generate the chemical starting point for such design programmes in rapid time, but to also predict whether the resulting molecules have the ‘druggable’ qualities required for human administration (e.g. absorption, solubility and metabolic stability), thereby reducing the cost, time and attrition associated with early development and increasing the likelihood of eventual clinical success.
The MolPlex Technologies were originally developed at Newcastle University and have three aspects:
• a vast in silico library of compounds that can be used for virtual screening to provide quick chemical starting points for new development programmes;
• a molecular simulations system that enables medicinal chemists to understand the interactions between drugs and their targets;
• algorithms that can predict the physiochemical properties of lead molecules (such as absorption, distribution, metabolism, excretion, cell permeability, solubility and plasma-protein binding), enabling rapid optimisation of candidates for clinical testing.
Dr Clive Dix, CEO of C4X Discovery, said: “These new technologies, which we have brought into the business on very economical terms, complement our existing platform and add to our ability to capitalise on the identification of high-value targets from our Taxonomy3® technology to generate drug candidates with greater clinical and commercial differentiation. We are rapidly building an internal pipeline of exciting therapeutic programmes and moving steadily towards realising our goal of becoming the world’s most productive drug discovery and development company.”
C4XD acquired the technologies from MolPlex Ltd, which is currently in administration, for a non-material amount.